Table A1.3Estimates of proportions

Parameter descriptionEstimate (%)
Patients in whom no cancer of the ovaries was detected following secondary care test:
Proportion of patients who are diagnosed with a benign gynaecological problem (for example a simple cyst)85
Proportion of patient who are diagnosed with ‘other’ cancer (colorectal)15
Patients in whom cancer of the ovaries was detected following secondary care test1:
Proportion of patients undergoing percutaneous biopsy (or any other histopathological investigation)35
Proportion of patients undergoing surgery60
Proportion of patients who are not fit to undergo any further investigation and receive supportive care5
Patients who have undergone surgery:
Proportion of patients in whom disease is confined to the ovaries (stage I)240
Proportion of patients in whom disease is not confined to the ovaries (stage II-IV)60
Patients with disease confined to the ovaries :
Proportion of patients undergoing chemotherapy (carboplatin)50
Proportion of patients who do not require further treatment (following surgery) and receive follow-up care50
Patients with disease not confined to the ovaries:
Proportion of patients undergoing chemotherapy (paclitaxel/carboplatin)85
Proportion of patients undergoing chemotherapy (paclitaxel/carboplatin) and further surgery10
Proportion of patients who are not fit for further treatment (following staging surgery) and are receiving supportive care5

Source:

GDG Consensus;

Warwick et al. 2009

Estimation is based on an assumption that of all patients in whom cancer of the ovaries is detected: 75% will have advanced stage disease and 25% will have early stage disease (Kosary 1994; Bell et al., 1998). Of those with advanced stage disease 50% will undergo surgery and 50% biopsy.

stage I includes stages Ia- Ic.

GDG Consensus;

From: Appendix 1, A cost-utility analysis of diagnostic investigations in primary care for women with symptoms of ovarian cancer

Cover of Ovarian Cancer
Ovarian Cancer: The Recognition and Initial Management of Ovarian Cancer.
NICE Clinical Guidelines, No. 122.
National Collaborating Centre for Cancer (UK).
Copyright © 2011, National Collaborating Centre for Cancer.

No part of this publication may be reproduced, stored or transmitted in any form or by any means, without the prior written permission of the publisher or, in the case of reprographic reproduction, in accordance with the terms of licenses issued by the Copyright Licensing Agency in the UK. Enquiries concerning reproduction outside the terms stated here should be sent to the publisher at the UK address printed on this page.

The use of registered names, trademarks etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore for general use.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.